Menu
Menu
đź“ŁExciting news! We are thrilled to welcome Argenetics Lab to our global community. The Argentinian company is a leader in genomics testing, offering comprehensive genomic solutions and solving all laboratory processes locally.
The lab will use our comprehensive, end-to-end application to further chronic lymphoma leukemia (CLL) research, allowing Argenetics to enter into the complex field of blood-derived cancers and becoming the first in Argentina to adopt this advanced NGS technology.
 “Our interest in Sophia Genetics is founded on their team's unparalleled expertise, technical precision, validation processes, optimized NGS workflow and powerful analytics platforms. We are particularly excited to implement their CLL application to streamline workflows for oncohematologists and support healthcare providers,” said
Gabriela Norese (https://www.linkedin.com/in/gabriela-norese-906308a9/), Medical Director at Argenetics lab (https://www.linkedin.com/company/laboratorio-argenetics/posts/?feedView=all).
This adoption of SOPHiA DDM™ into the Argentinian market has the potential to advance data-driven medicine and provide professionals with an expanded range of testing options to support their work. Â
"We are honored to work with Argenetics to support the adoption of data-driven medicine into Argentina, helping to bring world-class NGS testing to support healthcare researchers and clinicians who are working to improve outcomes for patients throughout Latin America,” said Ricardo Ramos Mendonca Filho, PhD., Managing Director, LAPAC, SOPHiA GENETICS. Â
Learn more about our solutions for blood cancers like leukemia here: https://sophiastg.wpenginepowered.com/clinical/oncology/blood-cancers/lymphoid-malignancies/
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
